天风证券给予百济神州买入评级,NON-GAAP口径下持续盈利,核心在研管线临床数据优异

每日经济新闻
13 Nov 2024

天风证券11月13日发布研报称,给予百济神州(688235.SH,最新价:175.73元)买入评级。评级理由主要包括:1)销售管理费用率逐季降低,连续两个季度实现NON-GAAP经营利润盈利;2)2024Q3核心品种泽布替尼美国区环比有增长,欧洲区保持环比快速增长;3)替雷利珠单抗在市场销售额持续增长,持续扩张全球版图;4)Sonrotoclax、BGB-16673在血液肿瘤中临床试验数据优秀。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10